Sarah Pringle

Sarah Pringle is a senior reporter focused on M&A, private equity and auctions in the healthcare industry. Prior to joining The Deal, Pringle reported on U.S. and Canadian equity markets at Bloomberg News in New York and MarketWatch in San Francisco.

Recent Articles By The Author

Abbott Looks to Kill Alere Deal

Abbott Looks to Kill Alere Deal

The medical device giant files a suit against Alere in the Delaware Court of Chancery hoping to walk away from their $7.9 billion merger agreement.

Questions Mount at Teva as Generics Head Quits Without Explanation

Questions Mount at Teva as Generics Head Quits Without Explanation

Siggi Olfasson is poised to step down as president and CEO of Teva's global generic medicines group by the end the first quarter of 2017.

PerkinElmer Medical Imaging Unit Sale Could Be in the Works

PerkinElmer Medical Imaging Unit Sale Could Be in the Works

Investors would also like to see the life science and tools company be more aggressive with its free cash flow.

Rolling Back Trade and Regulation Could Hurt Global M&A: Strine

Rolling Back Trade and Regulation Could Hurt Global M&A: Strine

President-elect Trump should heed the fallout over Brexit before tearing up treaties and regulation, the chief justice of the Delaware Supreme Court warns.

Allergan Seeks to Reassure Antsy Investors but Will They Buy It?

Allergan Seeks to Reassure Antsy Investors but Will They Buy It?

Will investors want to wait 12 to 18 months to see Allergan's deals pay dividends?